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Since the discovery of the anticancer activity of cisplatin by Rosenberg, extensive 
research has been carried out in order to develop new and more efficient platinum-
containing drugs. In recent years, platinum(IV) compounds are appealing due to their 
inertness and high lipophilicity. On the other hand, interest in organometallic platinum 
compounds such as cyclometallated platinum(II) compounds is based on their stability 
and on the fact that the presence of a (Pt-C) bond increases the lability of the ligand in 
trans. In contrast, cyclometallated platinum(IV) compounds which combine the 
properties imparted by the presence of a platinum(IV) centre and a cyclometallated ligand 
have received little attention. The aim of this review is to present the results obtained so 
far for cyclometallated platinum(IV) compounds tested as antitumour agents. These 
compounds are prepared either by intramolecular oxidative addition from electron-rich 
platinum precursors and adequate ligands or by intermolecular oxidative addition to 




cyclometallated platinum(IV) compounds containing one, two or three carbon donor 
ligands exhibit a remarkable cytotoxicity, in most cases greater than that of cisplatin, 
against a panel of human cancer cell lines. In contrast, compounds containing a [C,N] 
platinacycle are less active. For the most active tridentate [C,N,N’] platinum(IV) 
compounds studies of DNA interaction, topoisomerase I, II, and cathepsin B inhibition 
and ROS generation are presented. 






Platinum compounds have had a tremendous impact in several areas of inorganic 
chemistry such as coordination and organometallic chemistry and also in the 
establishment of reaction mechanisms. The existence of cis and trans isomers of 
[PtCl2(NH3)2] led Werner to infer a square-planar geometry for platinum(II) compounds 
while the study of the mechanisms of substitution reactions and of the trans effect in 
square-planar complexes were mostly investigated with platinum compounds. 
Concerning the development of organometallic chemistry, the first compound containing 
an unsaturated hydrocarbon attached to a metal was K[PtCl3(C2H4)]·H2O known as 
Zeise’s salt, and -bonded compounds containing a trimethylplatinum(IV) group 
described by Pope and Peachey in 1907 are also historically significant [1]. Moreover, 
since the work from Shilov in the early 1970s, platinum has played an important role in 
the study of C-H bond activation chemistry [2]. Finally, there is no doubt about the 
tremendous impact in the bioinorganic chemistry area of the discovery of the anticancer 
activity of cisplatin by Rosenberg [3] which was followed by an extensive research 
focused on the development of platinum compounds as potential therapeutics [4-8]. 
In spite of the variety of platinum compounds that have been studied in relation to their 
potential properties as anticancer agents, cyclometallated platinum(IV) compounds have 
received very little attention. In this review, we will present the results obtained so far for 
this type of compounds. In order to have a better understanding of the potential of 
cyclometallated platinum(IV) compounds as antitumor drugs, we will first analyse briefly 
the features of platinum (IV) versus platinum(II) (section 2) and of organometallic 




finally focus on the research concerning cyclometallated platinum(IV) compounds as 
potential antitumor agents carried out in our group (section 4). 
 
2.- PLATINUM(IV) VERSUS PLATINUM(II) ANTICANCER DRUGS 
Since the discovery of the anticancer activity of cisplatin by Rosenberg [3], extensive 
research has been carried out in order to develop new and more efficient metal-containing 
drugs. The mechanism of action of cisplatin involves substitution of chlorido ligands for 
water molecules upon tumour cell entry, which is followed by binding to DNA 
nucleobases and tumour cell apoptosis or programmed cell death [5]. Currently, there are 
three platinum-based anticancer drugs used world-wide: cisplatin, carboplatin and 
oxaliplatin, while three more platinum(II) compounds have been approved for use in 
humans: nedaplatin, lobaplatin and heptaplatin (see figure 1). All the clinically used drugs 
are neutral square-planar platinum(II) compounds containing two mutually cis non-labile 
ligands (either two monodentate ammine or a bidentate diamine) and two labile or semi 
labile ligands mutually cis (two chlorido ligands or a chelate O,O ligand) and this 
arrangement allows for a cytotoxic effect analogous to that of cisplatin [5, 9-11]. 
Recently, many efforts are dedicated to investigate “non classical platinum complexes” 
that may operate through distinct mechanisms such as trans-platinum(II) compounds, in 
which the leaving ligands are mutually trans [12], monofunctional platinum(II) 
compounds with only one labile ligand [13], platinum(II) compounds that act as 






Fig. 1.- The six platinum anticancer drugs approved for anticancer treatment in humans (cisplatin, 
carboplatin and oxaliplatin are used worldwide, nedaplatin, heptaplatin and lobaplatin are 
approved in Japan, Korea and China, respectively). Leaving ligands are indicated in red. 
 
Platinum(IV) complexes were already investigated  by Rosenberg but since they were 
less effective than cisplatin they were not studied in depth. In recent years, renewed 
interest in platinum(IV) compounds as new anticancer agents is based on the idea that 
they are capable of overcoming some of the problems associated with the platinum(II) 
drugs such as severe side effects and acquired resistance [5, 9-11, 17-19]. Platinum(IV) 
complexes have an octahedral geometry and are considered inert towards substitution 
reactions due to their low spin t2g6 configuration. The idea underlying the design of 
platinum(IV) anti-tumour agents is that these compounds will be stable outside the cell, 
and will be activated by two-electron reduction only inside the cancer cell. Intracellular 
reduction can be produced in the hypoxic environments of cancer cells, which contain a 
high concentration of reducing agents, leading to the cytotoxic square-planar platinum(II) 





Fig. 2.- Reduction of platinum(IV) prodrugs 
 
The reduction of the platinum(IV) compounds is a relevant step [20-21], since if the 
reduction takes place before the prodrug reaches the tumour or, on the contrary, if the 
compound is resistant to reduction inside the cancer cell, the compound is probably 
inactive. Information on the ease of reduction of platinum(IV) to platinum(II) can be 
obtained by cyclic voltammetry and the reduction potential depends primarily on the 
nature of the axial ligands. It was observed that the reduction occurs more readily when 
the axial ligands are chlorido than when they are carboxylato and more readily for 
carboxylato than for hydroxido ligands. However, the cytotoxic properties are not only 
related to the reduction potentials but also to the rates of reduction [22,23], which are 
determined by the nature and concentrations of the reducing agents. Although it is 
generally assumed that small-molecules such as glutathione (GHS) or ascorbic acid are 
the cellular reducing agents for platinum(IV) compounds, the identity of in vivo 
reductants remains uncertain.  
Thus, the platinum(IV) complexes are considered prodrugs that can be administered 
orally, due to their inertness and higher lipophilicity, and the two additional ligands can 
be used to improve the pharmacological properties in several ways such as increase the 
lipophilicity, co-deliver bioactive ligands, or attach the prodrug to delivery systems [9,10, 




that the platinum(II) precursor should be active [9,18,25]. A common strategy is to 
combine a known drug, analogous to cisplatin, with axial ligands that may introduce an 
additional function.  
Complexes of platinum(IV) can be obtained via two-electron oxidation of the 
platinum(II) precursors [26]. The most widely used oxidizing agents are hydrogen 
peroxide and chlorine which produce trans addition products in which the equatorial 
ligands retain the stereochemistry of the starting platinum(II) compound (paths a and b in 
scheme 1). As shown in scheme 1, platinum(IV) dihydroxido compounds are important 
starting materials for the synthesis of dicarboxylato complexes (see path c in scheme 1) 
[27]. In view of the relevance of the axial ligands to adjust important parameters of the 
platinum(IV) such as reduction potential, lipophilicity and solubility, the synthesis of 
compounds with two distinct axial ligands has also been pursued [28-30]. This can be 
achieved by maintaining a free hydroxido group during the derivatization reaction of a 
trans-dihydroxido compound (see path d in scheme 1) or using an alcohol as a solvent for 
the H2O2 oxidative addition (see path e in scheme 1). In recent years, the use of easy to 
handle iodobenzene dichloride (PhICl2) rather than chlorine gas facilitates the synthesis 
of dichloridoplatinum(IV) compounds [26]. In addition, the use of PhICl2 in aqueous 
acetone in the presence of tetrabutylammonium hydroxyde yields mixed trans-
hydroxydo-chlorido platinum(IV) compounds [19]. Oxidative addition of bromine or 
iodine (path f in scheme 1) also produces the corresponding dihalidoplatinum(IV) 
complexes [31] while the use of N-halosuccinimides as oxidizing agent allows for the 





Scheme 1.- Several common strategies for the synthesis of platinum(IV) prodrugs. (a) 
oxidative addition of chlorine; (b) oxidative addition of hydrogen peroxide in water 
solution; (c) and (d) acetylation reactions of dihydroxido complexes to produce di and 
mono-carboxylato complexes; (e) oxidative addition of hydrogen peroxide in alcohol 
solution; (f) oxidative addition of bromine or iodine. 
 
Although no platinum(IV) complex has been approved yet for clinical use, several 
platinum(IV) prodrugs such as ormaplatin (tetraplatin), iproplatin, satraplatin and LA-12 
(shown in figure 3) have undergone clinical trials. Satraplatin is the platinum(IV) 
compound that advanced more in clinical trials and its behaviour indicate that 
platinum(IV) compounds are less inert than expected. The analyses of the plasma of 
patients indicated, in addition to the major metabolite which consists on the expected 
platinum(II) compound obtained from the loss of the two axial acetato ligands, the 
presence of two platinum(IV) metabolites in which one or two chlorido ligands were 




platinum(IV) complexes can be reduced by low molecular weight biological reducing 
agents such as glutathione and ascorbic acid, recent studies carried out for satraplatin in 
cancer cells extracts revealed that high-molecular-weight intracellular components such 
as nicotinamide adenine dinucleotide (NADH) and cytochrome c are responsible for 
reduction of platinum(IV) to platinum(II) [9,10,18]. In addition, four square-planar 
platinum(II) reduction products, containing two chlorido, two acetato or one chlorido and 
one acetato ligands, were identified upon reduction of compounds cis,cis,trans-
[PtCl2(NH3)(NH2R)(CH3CO2)2] (R = H, isopropyl or cyclohexyl), in contrast with the 
initial assumption that only the axial ligands are released in the reduction step [34].  
 
 
Fig. 3.- Platinum(IV) complexes that have entered clinical trials. Leaving groups in red, axial 
ligands in blue. 
 
Platinum(IV) complexes have an enormous potential as anticancer agents, but many 
questions still need to be explored. They are generally considered as prodrugs for active 
platinum(II) species, but, in spite of the initial assumption that axial ligands were lost,  as 




depending on the reducing agents. In addition, platinum(IV) compounds may be less inert 
than initially thought so that it is not totally certain that they are unable to bind to 
biomolecules without prior reduction [35,36]. The design of new types of platinum(IV) 
anticancer drug candidates is necessary in order to explore their biological activities and 
to develop more efficient  antitumour agents.  
 
3.- ORGANOMETALLIC COMPOUNDS AS ANTITUMOR AGENTS 
Recent studies indicate that organometallic compounds are promising anticancer agents 
in spite of the initial idea that these compounds would be unstable under physiological 
conditions [37-40]. Organometallic compounds combine the properties of the metallic 
centre and the organic ligands, and the presence of strong M-C bonds improves the 
stability of these compounds and greatly influences the lability of the other bonds present. 
In addition, organometallic compounds are easily modified and there is a wide range of 
C-donor ligands available so that rational design can be performed and structure-activity 
relationships can be established. Ferrocene, [Fe(5-C5H5)2] was the first organometallic 
compound for which antiproliferative properties were tested and a wide range of 
metallocenes were also investigated [40]. Among those, titanocene dichloride [Ti(5-
C5H5)2Cl2] displays a good in-vivo anticancer activity [40]. Other classes of 
organometallic complexes for which the anticancer activity has been studied are metal-
arenes, in particular those of ruthenium(II) and other low-spin d6 metal centres such as 
osmium(II) or iridium(III), metal complexes with N-heterocyclic carbene, and 







3.1.- Cyclometallated platinum(II) compounds 
Cyclometallated compounds are appealing since they are easily obtained for a wide range 
of different ligands and metals [41-43]. Following the success of cisplatin in 
chemotherapies, not only a number of this type of platinum(II) compounds have been 
prepared in order to study their biological properties, but attention has also been focused 
on other metals such as Pd(II), Au(III), Ru(II), Os(II), Rh(III) or Ir(III). The most common 
ligands in these compounds are nitrogen donor either acting as bidentate [C,N] or as 
tridentate [C,N,N’], [C,N,C] or [C,N,S] ligands in which the metallated carbon atom 
belongs to an aromatic group.  These compounds are generally more stable than acyclic 
compounds, and the presence of aromatic planar groups might favour intercalative 
binding to DNA through non-covalent - stacking interactions, while the labile positions 
in the coordination sphere of the metal favour covalent coordination to DNA as for 
cisplatin. Therefore a high cytotoxic activity may result from the combined effect of both 
modes of interaction operating for cyclometallated compounds.  
A large number of cyclometallated platinum(II) compounds containing bidentate [C,N] 
or tridentate [C,N,N’] ligands have been screened against tumour cells and their 
properties can be easily modified by introducing different substituents in the aromatic 
ring of the cyclometallated ligand or by using different ancillary ligands [44-67]. In these 
compounds, the presence of a (Pt-C) bond increases the stability, thus allowing them to 
reach the cell unaltered. In addition, the lability of the ligands trans to a strong M-C bond 
increases so that covalent coordination to DNA is favoured. It is interesting to point out 
that the presence of Pt-C bonds in platinum(II) complexes produces a sharp change over 




of three-coordinate species is favoured over the associative pathway expected for square-
planar platinum compounds [68,69]. Moreover, several cyclometallated platinum(II) 
anticancer agents display luminescence properties which make them potential 
luminescent probes for DNA in living cells and also allows easy tracing of their cellular 
uptake and distribution by using fluorescence microscopy [70-72]. For instance, 
cyclometallated platinum(II) complexes such as I in figure 4 display high cytotoxicity to 
a panel of cancer cell lines and a strong phosphorescence [73].  
 
3.2.- Other types of organometallic platinum compounds 
In addition to cyclometallated platinum(II) compounds, other types of organometallic 
platinum compounds have been analysed as antitumor agents. These compounds 
generally break the traditional structure-activity rules described for cisplatin and 
analogues according to which two mutually cis non-labile and two mutually cis labile 
ligands complete the square-planar coordination of platinum(II). Some relevant examples 





























R = alkyl, aryl, alkynyl
X = Cl, Br
















Fig. 4- Relevant examples of organometallic platinum(II) compounds investigated as  potential 
anticancer agents. 
 
Several organoplatinum(II) containing 1,4-cyclooctadiene (cod) and different organic 
ligands R such as alkyl, aryl or alkynyl have been prepared (see structure II in figure 4) 
and high antiproliferative activity has been found for compounds [PtRCl(cod)] and 
appreciable cytotoxicity for compounds [PtR2(cod)] or [PtRR’(cod)]. Interestingly, while 
[PtCl2(cod)] was not significantly active on HT-29 colon and MCF-7 breast cancer cells, 
[PtMeCl(cod)] exhibited promising antiproliferative effects [74-78].  
Compounds containing inert pentafluoro or polyfluorophenyl anionic ligands instead of 
chlorido have received considerable attention since these groups confer a high 
lipophilicity to the obtained compounds which allows for easier cellular uptake and 
reduced side effects. Thus, several platinum(II) compounds of general formula [PtR2L2] 
or [PtRClL2] in which R is a polyfluorophenyl group and L is a neutral ligand display 




polyfluorophenyl groups bound to platinum [78-81]. An example of this type of 
compounds is shown in structure III of figure 4. Organometallic platinum -complex 
dichlorido[2-N,N-dimethyl-(2-methylidene-cyclohex-1-yl)methylamino]platinum(II) 
displays a low cytotoxicity against Capan 1 and A431 cancer cell lines [82] and a family 
of organometallic platinum complexes containing -coordinated cis-cyclooctene, with 
the structure IV in figure 4, gave promising results against MB231 breast or renal 
carcinoma (RCC) cancer cell lines [83]. A new class of five-coordinate platinum(II) 
compounds containing sugar ligands and exhibiting a high cytotoxicity has been recently 
reported (see structure V in figure 4) [84]. 
In spite of the great interest focussed on the anticancer properties of platinum(IV) 
compounds, there are very few reports concerning organometallic platinum(IV) 
compounds.  A series of organometallic platinum(IV) compounds of general formulae I 
and II depicted in figure 5 display activity on leukaemia L1210 and on cisplatin resistant 
L1210/DDP cell lines although, according to the reduction potentials obtained by cyclic 
voltammetry, the polyfluorophenyl ligands greatly stabilise the platinum(IV) oxidation 
state and these compounds are difficult to be reduced [85]. Other examples of 
organoplatinum(IV) complexes studied as anticancer agents are compounds of general 
formula  [PtMe2X2(tBubpy)] (X = Cl or Br) (structure III in figure 5) that were prepared 
by oxidative addition of X2 to the corresponding platinum(II) and display higher cytotoxic 





Fig. 5- Relevant examples of organometallic platinum(IV) compounds investigated as potential 
anticancer agents. 
 
4.- CYCLOMETALLATED PLATINUM(IV) COMPOUNDS 
In spite of the great deal of attention focussed on platinum(IV) complexes  (see section 
2) and  on cyclometallated platinum(II) compounds (see section 3.1), cyclometallated 
platinum(IV) compounds, which combine the properties imparted by the presence of a 
platinum(IV) centre and a cyclometallated ligand, have received very little attention. 
Table 1 collects the antiproliferative activity on A-549 lung, MDA-MB-231 and MCF-7 
breast, and HCT-116 for the studied cyclometallated platinum(IV) compounds (2a-2f, 3a-
3d and 4g-4i) [87-90] along with the data obtained for cyclometallated platinum(II) 
precursors (1a-1f) and the reference cisplatin. 
4.1.- Synthesis and properties of cyclometallated platinum(IV) compounds 
The synthesis of cyclometallated platinum(IV) compounds can be accomplished by 
intramolecular C-X bond activation from adequate platinum(II) substrates and ligands or 





As initially reported by Anderson and Puddephatt [91] the use of electron-rich platinum 
precursors such as [Pt2Me4(-SMe2)2] allows formation of cyclometallated platinum(II) 
or platinum(IV) compounds upon reaction with adequately designed ligands. The former 
arise from intramolecular C-H bond activation followed by elimination of methane and 
the latter from intramolecular activation of C-X bonds (X = F, Cl, Br) (see Scheme 2). 
This method allows one-step synthesis of tridentate [C,N,N’] cyclometallated 
platinum(IV) compounds such as [PtMe2X(RCH=NCH2CH2NMe2] (X = F, Cl, Br; R = 
aryl) containing a fac-PtC3 arrangement involving the metallated aryl carbon and two 
methyl ligands. This synthetic strategy allows the synthesis of a variety of 
cyclometallated compounds with different substituents on the aryl ring [92-94] or 
different size of the chelate [N,N’] [95, 96]. Bidentate [C,N] cyclometallated platinum(II) 
compounds of general formula [PtMe2X(C6H4CH=NCH2Ar)L] in which L is a 
dialkylsulphide ligand which can be easily replaced by other ligands such as phosphines 





Scheme 2.- Synthesis of cyclometallated platinum(II) and platinum(IV) compounds from a 
dimethylplatinum(II) precursor [91-93]. 
 
In recent years, several diarylplatinum(II) compounds containing labile ligands such as  
dialkylsulphides have also been tested as metallating agents for the same class of 
dinitrogen ligands and these reactions produced [C,N,N’] cyclometallated platinum(IV) 
or platinum(II) compounds such as [PtAr2X(RCH=NCH2CH2NMe2)] or 
[PtAr(RCH=NCH2CH2NMe2)] depicted in scheme 3 [88, 99, 100].  
 
Scheme 3. - Synthesis of cyclometallated platinum(II) and platinum(IV) compounds from  
diarylplatinum(II) precursors [99]. 
Cyclometallated platinum(IV) compounds such as those shown in schemes 2 and 3 
display some characteristic features. In solid state, the analysis of the structures by X ray 
crystallography [92, 101] indicate a fac-PtC3 geometry of the three C-donor ligands and 
a mer-[C,N,N’] arrangement of the tridentate ligand. In solution, two isomers, both with 
the fac-PtC3 geometry, and with the [C,N,N’] ligand either in mer o fac arrangement are 
possible. Calculations carried out for compounds [PtMe2X(C,N,N’)] indicated a slightly 




On the other hand, intermolecular oxidative addition on cisplatin and analogues to prepare 
platinum(IV) prodrugs has been carried out mainly with oxidizing agents such as halogen 
or hydrogen peroxide (see scheme 1) [18,26,31].  It is generally observed that the set of 
equatorial ligands of the resulting platinum(IV) compounds retain the stereochemistry of 
the starting platinum(II) compound while the new ligands occupy the axial positions [102, 
103]. Similar oxidative addition reactions can yield cyclometallated platinum(IV) 
compounds from the corresponding cyclometallated platinum(II) compounds and this 
type of oxidative addition reactions is well established for reagents such as chlorine, 
iodine or alkyl halides [102, 104-109].  
Compounds 2a-2f (see Table 1) [87,90] were prepared from oxidative addition of methyl 
iodide on the corresponding cyclometallated platinum(II) compounds 1a-1f, that were 
obtained following reported procedures [95, 96]. Octahedral platinum(IV) compounds in 
which the new ligands are mutually trans were obtained and the 1H NMR spectra 
indicated in most cases the presence of one single isomer in which the NMe2 methyl 
groups and the CH2 proton atoms are diastereotopic due to the absence of a symmetry 
plane. Only for 2b, the presence in an amount of less than 10% of a second isomer arising 
from mer to fac-[C,N,N’] isomerization was observed in the 1H NMR spectrum. For the 
phosphine derivative 2f initial trans oxidative addition is followed by complete 
isomerization to place the bulky phosphine ligand in an axial position trans to the methyl 
group. The oxidative addition of iodine on [C,N,N’] cyclometallated platinum(II) 
compounds 1a-1d produced compounds 3a-3d, while the reactions of [C,N] 
cyclometallated platinum(II) compounds 1e and 1f gave very insoluble compounds that 




Compounds 4g-4i were prepared in a straightforward process consisting of intramolecular 
C-X bond activation (X = Cl or Br) of ligands 2-BrC6H4CH=NCH2CH2NMe2 or 2,6-
Cl2C6H3CH=NCH2CH2NMe2 upon reaction with diarylplatinum substrates [Pt2(4-
FC6H4)4(-SEt2)2] or [Pt2(4-MeC6H4)4(-SEt2)2] (see scheme 3) [88, 89]. 
As a whole, the set of [C,N,N’]-cyclometallated platinum(IV) compounds under study 
include complexes with two axial ligands of the same or of different nature, which contain 
a variable number of labile positions such as the halogenido ligands or the dimethylamino 
fragment of the tridentate ligands, and one, two or three carbon atoms. It is interesting to 
point out that the presence of an increasing number of Pt-C bonds produces more labile 
complexes in spite of the inertness attributed to the t2g6 electronic configuration and that 
platinum(IV) complexes containing a fac-PtC3 geometry are considered as “quasi-labile” 
systems [110,111].  
The stability of cyclometallated platinum(IV) compounds 2b-2d and 4g-4i  in the aqueous 
biological media was evaluated by recording the 1H NMR spectra of the compounds (1 
mM) in 50 mM phosphate buffer (in D2O, pD 7.40) with 2 drops of deuterated DMSO to 
solubilize the compounds in the media. Under these conditions, one or more solvato 
species arising from substitution of the labile ligands are detected, and remain stable for 
several days. Unfortunately, the low solubility of compounds 3a-3d arising from 
oxidative addition of iodine and containing just one C-donor ligand did not allow 
analogous studies for these compounds. 
The reactions of compounds containing two or three C-donor ligands including one axial 
methyl (2b-2d) or three Caryl-donor ligands (4g-4i) with an excess of ascorbic acid, a 




analogous conditions and no evidence of reduction to the corresponding platinum(II) 
compounds was observed, although new species, different to the solvato species initially 
formed, are detected and assigned to coordination of ascorbic acid to platinum. Analogous 
experiments with other reducing agents such as glutathione or cysteine were carried out 
for 2d and indicated coordination of these molecules to platinum(IV) without evidence 
of reduction. In line with these results, the large negative values of the reduction potentials 
obtained by cyclic voltammetry for compounds 4g-4i are in the same range than those 
reported for platinum(IV) complexes with polyfluoroaryl ligands [85] and much lower 
than that reported for compounds such as tetraplatin, satraplatin or iproplatin, thus 
implying that compounds 4g-4i are reluctant to be reduced [89].  
On the other hand, recent studies indicated that compound [PtCl3(4-
ClC6H4CH=N(CH2)3NMe2] arising from oxidative addition of chlorine to compound 1a 
and containing just one C-donor ligand is reduced by cysteine, glutathione and thiolactic 
acid and the kinetics of these reactions were monitored by UV-Vis spectrophotometry. In 
all cases, two consecutive reaction steps were found to occur, the platinum(IV) to 
platinum(II) reduction and the substitution of the remaining chlorido ligand by the 
reduction agent [112].  
These results indicate that the number of C-donor ligands in cyclometallated 
platinum(IV) compounds could be decisive in the ease of platinum(IV) to platinum(II) 







4.2.- Biological studies of cyclometallated platinum(IV) compounds 
The antiproliferative activity of the studied cyclometallated platinum(IV) compounds was 
tested on A-549 lung, MDA-MB-231 and MCF-7 breast, and HCT-116 cancer cell lines 
(Table 1 and figure 6). The [C,N,N’] cyclometallated platinum(IV) compounds obtained 
from platinum(II) precursors 1a-1d exhibited remarkable cytotoxicity in all the carcinoma 
cell lines studied. In particular, compounds 2a-2d with methyl and iodido axial ligands 
showed the lowest IC50 values, in most cases lower than those obtained for the 
corresponding precursors 1a-1d. The activity of compounds 3a, 3b and 3d containing two 
axial iodido ligands is similar to that of the parent platinum(II) compounds, while the 
cytotoxicity of compound 3c containing three iodido ligands is lower [87,90]. For 
compounds 4g, 4h and 4i containing a fac-PtC3 arrangement and a [C,N,N’] ligand 
derived from ethylenediamine, the results indicated that the fluorinated derivative 4g is 
less potent than 4h and 4i. Finally, compounds 2e and 2f containing a [C,N] metallacycle 






Table 1. Antiproliferative activity (IC50 M) on A-549 lung, MDA-MB-231 and MCF-7 
breast, and HCT-116 cancer cell lines for the studied cyclometallated platinum(II) 
precursors (1a-1f), cyclometallated platinum(IV) compounds (2a-2f, 3a-3d, 4g-4i) and 
cisplatin.a 
 
Platinum(II) compounds A-549 MDA-MB-231 MCF-7 HCT-116 
1a 
 
5.48 ± 3.49 8.30 ± 3.60 7.69 ± 0.750 6.29 ± 0.34 
1b 
 
9.62 ± 2.14 7.34 ± 0.59 31.26 ± 0.51 10.58 ± 0.22 
1c 
 
6.25 ± 2.66 10.18 ± 3.42 10.23 ± 0.48 7.05 ± 0.18 
1d 
 
9.80 ± 0.32 7.71  ± 1.00 13.83 ± 3.37 6.48 ± 1.27 
1e 
 






> 100 > 100 > 100 > 100 
Platinum(IV) compounds A-549 MDA-MB-231 MCF-7 HCT-116 
2a 
 
2.46 ± 0.24 2.34 ± 0.33 12.39 ± 0.76 5.43 ± 0.13 
2b 
 
2.62 ± 0.27 2.06 ± 0.51 7.86 ± 0.72 2.28 ± 0.26 
2c 
 
1.42 ± 0.13 3.45 ±  1.55 6.72 ± 0.43 1.26 ± 0.18 
2d 
 
3.40 ± 1.74 1.58  ±  0.58 10.02 ± 3.69 1.77 ± 0.59 
2e 
 






> 100 38.29  ±  7.44 > 100 30.54  ±  6.87 
3a 
 
4.69 ± 3.61 5.11 ±  2.21 8.42 ± 0.41 5.06 ± 0.10 
3b 
 
6.67 ± 1.30 7.25 ± 0.23 7.65 ± 0.11 3.95 ± 1.62 
3c 
 
23.0 ± 2.98 14.10 ± 4.07 32.00 ± nd 12.11 ± 0.69 
3d 
 
9.69 ± 0.43 7.25 ± 1.68 11.08 ± 0.83 5.13 ± 0.03 
4g 
 
11.6 ± 2.2 11.8 ± 0.5 19.3 ± 2.2 c 
4h 
 






3.1 ± 0.1 8.1 ± 0.1 14.6 ± 2.4 c 
cisplatinb 
 
9.30 ± 3.00 12.31 ± 0.40 24.84 ± 0.40 21.10 ± 1.34 
 
a Data are shown as the mean values of two experiments performed in triplicate with the 
corresponding standard deviations. b Cisplatin (cis-[PtCl2(NH3)2]) is taken as reference 
compound and values are taken from reference [87]. c Not studied. 
 
 
Fig. 6- Antiproliferative activity (IC50 M) of [C,N,N’] cyclometallated platinum(IV) compounds 
2a-2d, 3a-3d, 4g-4i, and cisplatin against A-549 lung, MDA-MB-231 and  MCF-7 breast and 
HCT-116 colon cancer cell lines. 
 
 




The interaction of cyclometallated platinum(IV) compounds with DNA was assessed by 
their ability to modify the electrophoretic mobility of the supercoiled closed circular (sc) 
and the open circular (oc) forms of pBluescript SK+ plasmid DNA.  Compounds 2a-2c, 
2e, 3a-3d and 4i did not modify the DNA tertiary structure, while compounds 2d, 2f, 4h 
and 4g induce significant changes in the mobility of plasmid DNA, altering the DNA 
tertiary structure as the standard reference cisplatin, although at higher concentrations 
(see Table 2). Although there is not a clear evidence, the obtained results point to the fact 
that the presence of bulky equatorial substituents such as aryl ligands (2d and 2f) instead 
of smaller ligands (2a-2c) and of iodido or bromido (4g, 4h) axial ligands rather than 
chlorido (4i) favour the covalent binding to DNA in agreement with a dissociatively 
activated substitution mechanism for this type of compounds [111].  
On the other hand, the fact that compounds 2a-2c did not modify the DNA migration in 
spite of their low IC50 values points to other mechanisms of action or biomolecular targets. 
To evaluate the ability of the investigated cyclometallated platinum(IV) complexes to 
intercalate into DNA, a topoisomerase-based gel assay was performed for most of the 
studied complexes (see Table 2). Supercoiled pBluescript plasmid DNA was incubated 
in the presence of topoisomerase I at increasing concentrations of the studied compounds. 
None of the tested compounds prevent unwinding of DNA by the action of topoisomerase 
I, indicating that these compounds are neither topoisomerase I inhibitors nor intercalators. 
Although intercalative binding to DNA through non-covalent - stacking interactions is 
favoured in planar platinum(II) cyclometallated compounds, such interactions are less 
likely for octahedral platinum(IV) compounds. To study an alternative biomolecular 




using a similar procedure than that reported above for topoisomerase I. Several of these 
compounds showed considerable topoisomerase II inhibitory activity, a remarkable 
result since this enzyme is the target for several anticancer agents.  
Cathepsin B inhibition assay was also performed for most of the compounds studied since 
this cysteine metalloprotease has been proposed to participate in metastasis, angiogenesis, 
and tumour progression. The compounds did not present significant inhibitory activity 
against cathepsin B except for compound 3a which shows a moderate activity. 
Reactive oxygen species (ROS) are by-products of cell metabolism such as hydrogen 
peroxide, superoxide, hydroxyl radical and singlet oxygen. Although high ROS levels 
might produce cell senescence or apoptosis, cancer cells are able to maintain higher ROS 
levels while evading apoptosis. As part of their biological activities in cancer cells certain 
platinum complexes are able to induce elevated ROS levels to an extent which cancer 
cells can no longer evade apoptosis. As part of the study of the cytotoxic effect of the 
cyclometallated platinum(IV) compounds, ROS generation on A-549 or on HCT-116 
cancer cells was tested for selected compounds (see Table 2). In most cases, a 
significantly increased ROS generation occurs in agreement with previous studies that 
reported enhanced ROS generation in cancer cells as a response to platinum(IV) 






Table 2. Summary of biological studies carried out for cyclometallated platinum(IV) 
compounds 2a-2f, 3a-3d, 4g-4i.a 
 
 Compound DNAb Topo I c Topo II d Cathepsine ROSf 
2a N N N N g 
2b N N 20M N N 
2c N N N N Y 
2d 100M N 10 M N Y 
2e N N 100 M N g 
2f 25  M N 25 M N g 
3a N N 20M Y g 
3b N N N N g 
3c N N 100M N g 
3d N N 50 M N Y 
4g 200 M g g N g 
4h 100 M g g N Y 
4i N N g N Y 
 
a See references [87, 89, 90] for further information; b In this column N indicates that the 
compound does not modify the plasmid DNA electrophoretic mobility; for compounds that alter 
the mobility of DNA the required concentration is indicated; c In this column N indicates that the 
compound is neither intercalator nor topoisomerase I inhibitor; d In this column N indicates that 
the compound is not a topoisomerase II inhibitor; for compounds that show inhibitory activity 
the required concentration is indicated; e In this column, Y indicates that the compound inhibits 
cathepsin B and N indicates that the compound does not show cathepsin B inhibitory activity;. f  
In this column Y indicates that the compound cause significant ROS generation after incubation 
with the cancer cell line A-549 (2c, 4h, 4i) or  HCT-116 (2d, 3d, 4h, 4i) and N  indicates that the 






Several cyclometallated platinum(IV) compounds have been prepared by intermolecular 
oxidative addition of either methyl iodide (2a-2f) or iodine (3a-3d) to the corresponding 
cyclometallated platinum(II) compounds. In addition, compounds 4h-4i were prepared 
by intramolecular oxidative addition of C-Br or C-Cl bonds of imine ligands to 
diarylplatinum(II) precursors. The tridentate [C,N,N’]-cyclometallated platinum(IV) 
compounds exhibited a remarkable cytotoxicity effectiveness against a panel of human 
adenocarcinoma (A-549 lung, HCT-116 colon, MDA-MB-231 and MCF-7 breast, and 
HCT-116) cell lines while bidentate [C,N]-cyclometallated platinum(IV) compounds are 
less active. 1H NMR experiments carried out in a buffered aqueous medium for 
compounds 2b-2d and 4g-4i containing two or three C-donor atoms in the presence of 
common biologically relevant reducing agents indicated coordination of these molecules 
to platinum(IV) without reduction to platinum(II) species. Compounds 2d, 2f, 4h and 4g 
induce significant changes in the mobility of plasmid DNA, altering the DNA tertiary 
structure as the standard reference cisplatin, although at higher concentrations. None of 
the compounds tested were topoisomerase I inhibitors, but several compounds (2b, 2d, 
2f, 3a, and to a lesser extent 2e, 3c or 3d) showed topoisomerase II inhibitory activity 
or the ability to induce ROS generation (2c, 2d, 3d, 4h or 4i). As a whole, the obtained 
results indicate that some of the [C,N,N’]-cyclometallated platinum(IV) compounds here 
described display a multitarget nature and a high potential to be used in cancer 
chemotherapy. The stability towards reduction, the lability and the biological properties 




completing the octahedral coordination around the platinum centre or the substituents in 
the aryl ring. In particular, further studies in our group will be aimed at analysing the 
effect of the presence of one, two or three Pt-C bonds in the properties and in the mode 
of action as drugs or prodrugs of this new class of promising antitumour agents 
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